Vertex was the first company to produce a medicine tackling the root cause of cystic fibrosis (CF) – mutations in a gene that codes for ion channels in cells that produce mucus, sweat ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

CEO Reshma Kewalramani praised Arbuckle for his work on Vertex's CF medicines, as well as helping "develop and lead the organization into this new era of commercial diversification." "Anyone who ...

Vertex enjoys a monopoly with its CF therapies and has three new potential blockbusters on the market. The company's powerhouse pipeline and hefty cash stockpile could fuel more growth in the future.

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

Vertex’s drugs combine both mechanisms to improve CFTR function at the surface of a cell. Waltham, Massachusetts-based Sionna is developing CF drugs that target NBD1, a domain on the CFTR protein.

The company aims to launch five new treatments by 2028, which include a next-generation CF drug and a non-opioid pain management medication. In December, Vertex entered into an agreement with the ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of $11 ...

Sionna’s novel mechanism is distinctive from that of the CF market leader, Vertex Pharmaceuticals, with its therapeutic approach of CFTR modulation. With Vertex dominating the CF market with ...